|Bid||0.008 x 128390500|
|Ask||0.009 x 125200000|
|Day's range||0.008 - 0.008|
|52-week range||0.006 - 0.012|
|PE ratio (TTM)||N/A|
|Earnings date||1 Mar. 2016 - 5 Mar. 2016|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.25|
MELBOURNE, Australia, Dec. 12, 2017-- Genetic Technologies Limited, a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGen plus ®, a first-in-class, clinically validated ...
MELBOURNE, Australia, Dec. 01, 2017-- Genetic Technologies Limited, advises that on 29 November it received a notice under Section 249 D of the Corporations Act 2001 requesting the Company call and arrange ...
Launched a three month promotional campaign leading up to and throughout October Breast Cancer Awareness Month BREVAGen plus commercial program to transition to an ecommerce based solution Ohio State University ...